全文获取类型
收费全文 | 24047篇 |
免费 | 1163篇 |
国内免费 | 121篇 |
专业分类
耳鼻咽喉 | 326篇 |
儿科学 | 396篇 |
妇产科学 | 491篇 |
基础医学 | 3045篇 |
口腔科学 | 606篇 |
临床医学 | 1781篇 |
内科学 | 6533篇 |
皮肤病学 | 264篇 |
神经病学 | 1772篇 |
特种医学 | 691篇 |
外科学 | 4108篇 |
综合类 | 110篇 |
一般理论 | 1篇 |
预防医学 | 739篇 |
眼科学 | 369篇 |
药学 | 1626篇 |
中国医学 | 42篇 |
肿瘤学 | 2431篇 |
出版年
2022年 | 215篇 |
2021年 | 410篇 |
2020年 | 236篇 |
2019年 | 264篇 |
2018年 | 390篇 |
2017年 | 299篇 |
2016年 | 361篇 |
2015年 | 375篇 |
2014年 | 533篇 |
2013年 | 656篇 |
2012年 | 1012篇 |
2011年 | 1140篇 |
2010年 | 604篇 |
2009年 | 549篇 |
2008年 | 1059篇 |
2007年 | 1135篇 |
2006年 | 1102篇 |
2005年 | 1033篇 |
2004年 | 1020篇 |
2003年 | 1000篇 |
2002年 | 1055篇 |
2001年 | 892篇 |
2000年 | 936篇 |
1999年 | 812篇 |
1998年 | 309篇 |
1997年 | 218篇 |
1996年 | 210篇 |
1995年 | 190篇 |
1994年 | 169篇 |
1993年 | 149篇 |
1992年 | 600篇 |
1991年 | 630篇 |
1990年 | 533篇 |
1989年 | 541篇 |
1988年 | 521篇 |
1987年 | 500篇 |
1986年 | 433篇 |
1985年 | 432篇 |
1984年 | 316篇 |
1983年 | 238篇 |
1979年 | 231篇 |
1978年 | 133篇 |
1977年 | 136篇 |
1974年 | 128篇 |
1973年 | 119篇 |
1972年 | 137篇 |
1971年 | 128篇 |
1970年 | 114篇 |
1969年 | 138篇 |
1967年 | 128篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
6.
Peroxisome proliferator-activated receptor delta (PPARdelta), a novel target site for drug discovery in metabolic syndrome. 总被引:5,自引:0,他引:5
Sadao Takahashi Toshiya Tanaka Tatsuhiko Kodama Juro Sakai 《Pharmacological research》2006,53(6):501-507
The development of new treatments for metabolic syndrome is urgent project for decreasing the prevalence of coronary heart disease and diabetes mellitus in the advanced countries. Peroxisome proliferator-activated receptor (PPAR)alpha and gamma agonists have shed light on the treatment of hypertriglyceridemia and type 2 diabetes mellitus, respectively. Among PPARs, analysis of the PPARdelta functions is lagging behind because specific PPARdelta agonists have not been developed. The appearance of new PPARdelta agonists is brightening the prospects for elucidating the physiological role of PPARdelta. PPARdelta is a new target for the treatment of metabolic syndrome. In particular, the fact that fatty acid oxidation and energy dissipation in skeletal muscle and adipose tissue by PPARdelta agonists lead to improved lipid profile, reduced adiposity and insulin sensitivity is a breakthrough. It seems that treatment of PPARdelta agonists operate similarly to the caloric restriction and prolonged exercise. We suggest that the physiological role of PPARdelta may be an indicator for switching from glucose metabolism to fatty acid metabolism. To receive new benefits of PPARdelta agonists against metabolic syndrome by increasing fatty acid consumption in skeletal muscle and adipose tissue, we need to unveil more details on the functions of PPARdelta itself and its agonists in the future. 相似文献
7.
Koji Saito Takashi Saito Sumio Kawada 《Nihon Shokakibyo Gakkai zasshi》2006,103(10):1176, 1179-1176, 1180
8.
Masahiro Yamauchi Hiroko Kusano Etsuko Saito Takeshi Iwata Masashi Nakakura Yasuki Kato Takaaki Uochi Shiro Akinaga Noboru Aoki 《Journal of controlled release》2006,114(2):268-275
Previously, we demonstrated that wrapping dextran fluorescein anionic/cationic lipid complexes with neutral lipids produced a stable formulation that markedly increased the duration of the compound in plasma after intravenous administration to rats. The improved drug-delivery properties of the wrapped liposomes (WL) relative to other formulations suggested that this technology could offer important advantages for the administration of other polyanionic drugs, including antisense oligodeoxynucleotides (ODN). In the present study, we investigated the value of WL for formulating fluorescence-labeled phosphorothioated ODN (F-ODN). WL encapsulating F-ODN/cationic lipid complexes were prepared efficiently using similar methodology to that used in our earlier study. Studies confirmed that these WL were stable in vitro. Following intravenous administration to mice, free F-ODN and naked F-ODN/cationic lipid complexes were rapidly eliminated whereas administration of the WL resulted in high blood concentrations of drug that were maintained for several hours. Additional studies were conducted in mice that were inoculated with tumor cells (Caki-1 xenograft model, human kidney); in these experiments, intravenous administration of WL delivered 13 times more F-ODN to the tumor site than achieved after injection of free F-ODN. 相似文献
9.
10.
Y Ohtsuka X-T Wang J Saito T Ishida M Munakata 《The European respiratory journal》2006,28(5):1013-1019
Inter-individual variations in the development of silicosis, even within the same environments, have been reported, which suggest the contribution of genetic factors in silicosis aetiology. The aim of the present study was to determine whether there is any significant genetic influence on the development of silicosis. Furthermore, which genetic loci are responsible for the pulmonary response to silica exposure? Eight strains of inbred mice were used to examine the genetic influence on the lung fibrotic response to silica exposure. After intercross-breeding between the most susceptible and most resistant strains, a genome-wide linkage analysis of quantitative trait loci (QTL) was performed. Hydroxyproline was applied as an index, and genotypes of 167 marker genes were analysed by fragment analysis using a capillary-type sequencer. There was significant inter-strain difference in the mean concentration of hydroxyproline contents among the eight strains of mice. Breeding studies were conducted between the most susceptible, C57BL/6J, and the most resistant strain, CBA/J. A genome-wide linkage analysis of silica-exposed intercrossed cohorts identified significant QTL on chromosome 4 and suggestive QTL on chromosomes 3 and 18. The present study demonstrates that genetic factors may play a significant role in fibrotic-lung responses to silica; one significant and two suggestive quantitative trait loci were identified. 相似文献